Schizophrenia has still unknown causes, although they may be related to dopaminergic hyperfunction and glutamatergic hypofunction, in addition to a possible link with neuroinflammation. Despite its imprecise origin, there are hypotheses about neurodevelopmental disorder leading to animal models based on interventions during this phase. One of these models is the treatment with methylazoxymethanol acetate (MAM), which consists of the injection of this neurotoxin on the 17th day of gestation of Wistar rats, causing damage to the neurodevelopment of the offspring. In their adult phase, these animals present behavioral deficits and neurochemical alterations that resemble some schizophrenia symptoms, including the loss of parvalbumin positive (PV +) interneurons. In recent studies in our laboratory, the antioxidant N-acetyl-L-cysteine (NAC) was able to reverse behavioral deficits caused by the MAM model. In addition, sub-chronic treatment with the nitric oxide precursor, 1-arginine, reversed the beneficial effects of NAC. Thus, the present study intends to investigate: i) the expression of glial markers (GFAP-astrocytes and Iba-1 microglia) and PV + in the pre-frontal cortex of MAM rats treated with NAC or saline for 15 days. It is intended to test both the inflammatory hypothesis in the MAM model and the efficacy of the NAC treatment in reversing the dysfunctions caused in this model. If alterations caused by NAC are detected, it will be investigated whether subchronic treatment with L-arginine (5 days) reverses such changes, according to the behavioral results observed.
News published in Agência FAPESP Newsletter about the scholarship: